Positive Interim Data from ATH434-202 Phase 2 Clinical Trial
Alterity Therapeutics announces positive interim data from ATH434-202 Phase 2 trial in MSA patients.
Alterity Therapeutics
ATH434
Multiple System Atrophy
Clinical Trial
Biotechnology
Posted on: 17/07/2024
Read More